Tag Archives: Modulight in science

Screening of photosensitizers-ATP binding cassette (ABC) transporter interactions in vitro

Published in: Cancer Drug Resistance Authors: Shruti Vig1, Payal Srivastava1,#, Idrisa Rahman1,2,#, Renee Jaranson1, Anika Dasgupta1, Robert Perttilä3, Petteri Uusimaa3, Huang-Chiao Huang1  Published in: Cancer Drug Resistance Authors: Shruti Vig1, Payal Srivastava1,#, Idrisa Rahman1,2,#, Renee Jaranson1, Anika Dasgupta1, Robert Perttilä3, Petteri Uusimaa3, Huang-Chiao Huang1 University of Maryland and Modulight have published together a new research study about the mechanisms of cancer drug resistance. Drug resistance is a leading cause of treatment failure and often has dramatic consequences for survival of cancer patients. Cancer cells have developed various ways to protect themselves from drugs. When several clinically used photoactive drugs were studied, it was shown that some of them were being actively pumped out by cancer cells, thus likely limiting the full therapeutic potential of these Continue reading →

Carrier-Free, Amorphous Verteporfin Nanodrug for Enhanced Photodynamic Cancer Therapy and Brain Drug Delivery

Published in: Advanced Science Authors: John A. Quinlan, Collin T. Inglut, Payal Srivastava, Idrisa Rahman, Jillian Stabile, Brandon Gaitan, Carla Arnau Del Valle, Kaylin Baumiller, Anandita Gaur, Wen-An Chiou, Baktiar Karim, Nina Connolly, Robert W. Robey, Graeme F. Woodworth, Michael M. Gottesman, Huang-Chiao Huang University of Maryland  Published in: Advanced Science Authors: John A. Quinlan, Collin T. Inglut, Payal Srivastava, Idrisa Rahman, Jillian Stabile, Brandon Gaitan, Carla Arnau Del Valle, Kaylin Baumiller, Anandita Gaur, Wen-An Chiou, Baktiar Karim, Nina Connolly, Robert W. Robey, Graeme F. Woodworth, Michael M. Gottesman, Huang-Chiao Huang University of Maryland Glioblastoma (GBM) is hard to treat due to cellular invasion into functioning brain tissues, limited drug delivery, and evolved treatment resistance. Recurrence is nearly universal even after surgery, chemotherapy, and radiation. Photodynamic therapy (PDT) involves photosensitizer administration followed by light activation to generate reactive oxygen species at tumor sites, thereby killing cells or Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – July 2022

 Modulight Spotlights: LASER-SHARP RESEARCH – July 2022 Modulight congratulates Dr. Makoto Mitsunaga et al. Jikei University School of Medicine for publishing their promising results in Communications Biology journal. The team developed a next-generation light-based approach to tackle pathogens, called photoimmuno-antimicrobial strategy (PIAS). This technology was shown to eliminate a broad spectrum of different classes of pathogens, such as viruses, fungi, and bacteria. Unlike antibiotics, PIAS was also effective against drug-resistant pathogens and didn’t damage natural, beneficial microbiota in the host’s tissues. As COVID-19 pandemic and Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – February 2022

   Modulight Spotlights: LASER-SHARP RESEARCH – February 2022 Photocure’s blue light cystoscopy is a routine procedure in the management of bladder cancer as it results in better tumor visualization and removal. However, this study found that the positive effects of blue light cystoscopy could extend beyond visualization and result in the induction of systemic antitumor immunity, which can be further boosted with immune checkpoint inhibitors. Modulight nominated this study because bladder cancer is highly recurring and progressive disease with more than 200,000 deaths worldwide annually. Thus, Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – November 2021

     Modulight Spotlights: LASER-SHARP RESEARCH – November 2021 Dr. Aaron Sorrin and researchers at the University of Maryland found a new potential combination therapy for ovarian cancer. This combination includes a novel light-based technology, called photodynamic priming, and a targeted therapeutic against a specific cancer cell receptor, effectively suppressing invasion of cancer cells. Modulight’s scientific board wanted to highlight this research especially because novel therapeutic solutions are urgently needed against this aggressive disease, which despite the best possible current therapies, recurs in most patients leading to Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – October 2021

   Modulight Spotlights: LASER-SHARP RESEARCH – October 2021 This time we wanted to highlight Professor Tebello Nyokong’s team at Rhodes University, since their latest research tackles two big unmet needs in cancer therapy: tumor hypoxia and side effects of the drugs. The team designed multifunctional liposomes that can locally generate oxygen within tumors to alleviate hypoxia, which is a significant contributor to resistance to radio- and chemotherapies. These nanodrugs also hold the potential to reduce problematic side effects of standard cancer therapies as a result of Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – September 2021

 Modulight Spotlights: LASER-SHARP RESEARCH – September 2021 Laser-Sharp Research nomination goes to this month for Professor Kobayashi’s team and Dr. Noriko Sato’s team at National Cancer Institute, National Institute of Health, USA. Their research published in a prestigious Cancer Research journal showed that photoimmunotherapy can not only target tumor cells, but can also be harnessed to target body’s own tumor-promoting immune cells within the tumor. These special cells called intratumoral Tregs were selectively killed by photoimmunotherapy upon illumination with ML7710 laser, which led to activation Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – August 2021

 Modulight Spotlights: LASER-SHARP RESEARCH – August 2021 Modulight would like to congratulate Dr. Sabrina Oliveira and members of the Molecular Targeted Therapies research group at Utrecht University on their recent work published in Nanophotonics journal. They have developed nanobody-targeted phototherapy for feline oral carcinoma with high potency and specificity towards oral cancer cells. This is an important step towards treating cats with oral cancers for which there are currently no effective therapeutic options available in the veterinary clinics. This type of research overall is critical Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – July 2021

 Modulight Spotlights: LASER-SHARP RESEARCH – July 2021 Congratulations for Gina Manda and her team at Victor Babes National Institute of Pathology! Their genetic study unveiled a network of stress responses in tumor cells triggered by PDT. These results expand knowledge of different mechanisms behind therapy-induced cell death and treatment resistance. Read original publication   Modulight is very happy to be supporting this research. We would like to deliver our warmest congratulations to the research team!   #LaserSharpResearch  #ModulightInScience   #LasersInScience #KillCancer  #ColonCancer #Genetics     Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – June 2021

Modulight Spotlights: LASER-SHARP RESEARCH – June 2021 The findings by Prof. Lothar Lilge and his team might enable improved treatment of diffuse lung metastasis which are difficult to treat with standard therapies. A novel lung perfusion platform significantly reduced tissue absorption and allowed better light penetration, resulting in up to 3-fold increased treatment volumes.   Read original publication   Modulight is very happy to be supporting this research. We would like to deliver our warmest congratulations to the research team!   #LaserSharpResearch  #ModulightInScience   #LasersInScience Continue reading →